- Home
- PPBT vs SNES Comparison
PPBT vs SNES Comparison
Compare PPBT & SNES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- SNES
- Stock Information
- Founded
- PPBT 2010
- SNES 2004
- Country
- PPBT Israel
- SNES United States
- Employees
- PPBT N/A
- SNES N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- SNES Agricultural Chemicals
- Sector
- PPBT Health Care
- SNES Industrials
- Exchange
- PPBT Nasdaq
- SNES Nasdaq
- Market Cap
- PPBT 6.3M
- SNES 6.7M
- IPO Year
- PPBT N/A
- SNES 2016
- Fundamental
- Price
- PPBT $2.34
- SNES $4.80
- Analyst Decision
- PPBT Strong Buy
- SNES Strong Buy
- Analyst Count
- PPBT 1
- SNES 1
- Target Price
- PPBT $33.00
- SNES $10.00
- AVG Volume (30 Days)
- PPBT 29.4K
- SNES 228.1K
- Earning Date
- PPBT 08-15-2025
- SNES 08-07-2025
- Dividend Yield
- PPBT N/A
- SNES N/A
- EPS Growth
- PPBT N/A
- SNES N/A
- EPS
- PPBT N/A
- SNES N/A
- Revenue
- PPBT N/A
- SNES $1,927,000.00
- Revenue This Year
- PPBT N/A
- SNES $130.53
- Revenue Next Year
- PPBT N/A
- SNES $80.00
- P/E Ratio
- PPBT N/A
- SNES N/A
- Revenue Growth
- PPBT N/A
- SNES 40.15
- 52 Week Low
- PPBT $2.00
- SNES $1.30
- 52 Week High
- PPBT $13.95
- SNES $6.48
- Technical
- Relative Strength Index (RSI)
- PPBT 41.27
- SNES 76.68
- Support Level
- PPBT $2.30
- SNES $3.56
- Resistance Level
- PPBT $2.45
- SNES $4.46
- Average True Range (ATR)
- PPBT 0.14
- SNES 0.38
- MACD
- PPBT -0.03
- SNES 0.10
- Stochastic Oscillator
- PPBT 16.58
- SNES 97.61
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.